je.st
news
Tag: annual meeting
Findings Presented at 2015 ASCO Annual Meeting Add to Breadth of KEYTRUDA (pembrolizumab) Data; Anti-Tumor Activity Now Demonstrated in 13 Different Tumor Types
2015-06-01 14:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. New Data Presented at ASCO in Multiple, Difficult-to-Treat Cancers, including Small Cell Lung, Esophageal and Ovarian Cancers Registrational Studies for KEYTRUDA Ongoing in Eight Different Tumor Types KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first-time presentation of findings investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in multiple, difficult-to-treat cancers, including advanced small cell lung cancer (SCLC), esophageal cancer and ovarian cancer from the KEYNOTE-028 Phase 1b study. Language: English Contact: MerckMedia:Pamela Eisele, 267-664-0282orClaire Mulhearn, 908-200-1889orInvestors:Joseph Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: add
data
types
presented
First Study Evaluating DNA Mismatch Repair as Genetic Guide for Immunotherapy Treatment with Mercks KEYTRUDA (pembrolizumab) Presented at 2015 ASCO Annual Meeting and Published in the New England Journal of Medicine
2015-05-29 20:05:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Early Findings Show DNA Mismatch Repair-Deficient Colorectal and Other Tumors Highly Responsive to Checkpoint Blockade with Anti-PD-1 Therapy Merck Plans to Initiate Phase 2 Registrational Study with KEYTRUDA (KEYNOTE-164) to Evaluate MMR-Deficiency in Colorectal Cancer KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from the first study evaluating the correlation of benefit with an immunotherapy based on DNA mismatch repair (MMR) deficiency, a well-established form of genetic instability in many cancers characterized by the loss of function of the MMR pathway. Language: English Contact: MerckMedia:Pamela Eisele, 267-664-0282Claire Mulhearn, 908-200-1889orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Notice for Annual General meeting of Dome Energy AB (publ) on June 25 2015
2015-05-29 15:21:49| Appliances - Topix.net
The shareholders of Dome Energy AB , org. nr 556533-0189, , are hereby invited for annual general meeting on Thursday June 25 at 10.00 at Park Venue on Engelbrektsgatan 9-11 in Stockholm.
Notice of Annual General Meeting in Petrogrand Ab
2015-05-25 09:40:18| Appliances - Topix.net
The shareholders in Petrogrand AB , reg. no. 556615-2350 are hereby convened to the annual general meeting on Tuesday 23 June, 2015 at 3.00 p.m., at Be recorded in the shareholders' register which is kept by Euroclear Sweden AB , not later than Tuesday 16 June 2015 and notify the Company of their attendance and any attending assistants no later than Tuesday 16 June 2015, either in writing to Petrogrand AB , Birger Jarlsgatan 41A, 111 45 Stockholm, or via e-mail agm@petrogrand.se stating the full name, and preferably personal registration number or corporate registration number, address, telephone, number of shares and when applicable, information regarding assistant, and preferably information regarding legal representative, proxy.
Tags: general
notice
meeting
annual
Kinnevik: Annual General Meeting 2015
2015-05-18 18:36:10| Appliances - Topix.net
Investment AB Kinnevik today held its Annual General Meeting . The AGM resolved in accordance with all proposals of the Board and the Nomination Committee.
Tags: general
meeting
annual
annual meeting
Sites : [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] next »